J Bacteriol Virol.  2015 Jun;45(2):159-164. 10.4167/jbv.2015.45.2.159.

Differential Regulation of NF-kappaB Signaling during Human Cytomegalovirus Infection

Affiliations
  • 1Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea. jahn@skku.edu

Abstract

NF-kappaB transcription factors are key regulators of immune and stress responses, apoptosis, and differentiation. Human cytomegalovirus (HCMV) activates or represses NF-kappaB signaling at different times during infection. An initial increase in NF-kappaB activity occurs within a few hours of infection. The virus appears to adapt to this change since initial viral gene expression is promoted by the elevated NF-kappaB activity. Because NF-kappaB upregulates innate immune responses and inflammation, it has also been suggested that HCMV needs to downregulate NF-kappaB signaling. Recent studies have shown that HCMV has various mechanisms that inhibit NF-kappaB signaling. HCMV reduces cell surface expression of tumor necrosis factor receptor 1 (TNFR1) and blocks the DNA binding activity of NF-kappaB. Furthermore, some HCMV tegument proteins antagonize NF-kappaB activation by targeting the key components of NF-kappaB signaling at late stages of infection. In this review, we summarize the recent findings on the relationship between HCMV and NF-kappaB signaling, focusing, in particular, on the viral mechanisms by which the NF-kappaB signaling pathway is inhibited.

Keyword

Cytomegalovirus; NF-kappaB; Immune response; Tegument protein

MeSH Terms

Apoptosis
Cytomegalovirus
Cytomegalovirus Infections*
DNA
Genes, Viral
Humans
Immunity, Innate
Inflammation
NF-kappa B*
Receptors, Tumor Necrosis Factor
Transcription Factors
DNA
NF-kappa B
Receptors, Tumor Necrosis Factor
Transcription Factors

Reference

1). Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, editors. Fields virology. 5th ed.Philadelphia, PA: Lippincott Williams & Wilkins;2007.
2). Stenberg RM. The human cytomegalovirus major immediate-early gene. Intervirology. 1996; 39:343–9.
Article
3). Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling pathways. Nat Immunol. 2011; 12:695–708.
4). Kowalik TF, Wing B, Haskill JS, Azizkhan JC, Baldwin AS Jr, Huang ES. Multiple mechanisms are implicated in the regulation of NF-kappa B activity during human cytomegalovirus infection. Proc Natl Acad Sci U S A. 1993; 90:1107–11.
Article
5). Sambucetti LC, Cherrington JM, Wilkinson GW, Mocarski ES. NF-kappa B activation of the cytomegalovirus enhancer is mediated by a viral transactivator and by T cell stimulation. EMBO J. 1989; 8:4251–8.
Article
6). Yurochko AD, Huang ES. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol. 1999; 162:4806–16.
7). Yurochko AD, Hwang ES, Rasmussen L, Keay S, Pereira L, Huang ES. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J Virol. 1997; 71:5051–9.
Article
8). Yurochko AD, Mayo MW, Poma EE, Baldwin AS Jr, Huang ES. Induction of the transcription factor Sp1 during human cytomegalovirus infection mediates upregulation of the p65 and p105/p50 NF-kappaB promoters. J Virol. 1997; 71:4638–48.
Article
9). Johnson RA, Huong SM, Huang ES. Activation of the mitogen-activated protein kinase p38 by human cytomegalovirus infection through two distinct pathways: a novel mechanism for activation of p38. J Virol. 2000; 74:1158–67.
Article
10). Johnson RA, Ma XL, Yurochko AD, Huang ES. The role of MKK1/2 kinase activity in human cytomegalovirus infection. J Gen Virol. 2001; 82:493–7.
Article
11). Yurochko AD, Kowalik TF, Huong SM, Huang ES. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters. J Virol. 1995; 69:5391–400.
Article
12). Jiang HY, Petrovas C, Sonenshein GE. RelB-p50 NF-kappa B complexes are selectively induced by cytomegalovirus immediate-early protein 1: differential regulation of Bcl-x(L) promoter activity by NF-kappa B family members. J Virol. 2002; 76:5737–47.
13). Wang X, Sonenshein GE. Induction of the RelB NF-kappaB subunit by the cytomegalovirus IE1 protein is mediated via Jun kinase and c-Jun/Fra-2 AP-1 complexes. J Virol. 2005; 79:95–105.
14). Billstrom Schroeder M, Worthen GS. Viral regulation of RANTES expression during human cytomegalovirus infection of endothelial cells. J Virol. 2001; 75:3383–90.
Article
15). Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, et al. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003; 77:4588–96.
Article
16). Grundy JE, Lawson KM, MacCormac LP, Fletcher JM, Yong KL. Cytomegalovirus-infected endothelial cells recruit neutrophils by the secretion of C-X-C chemokines and transmit virus by direct neutrophil-endothelial cell contact and during neutrophil transendothelial migration. J Infect Dis. 1998; 177:1465–74.
Article
17). Hirsch AJ, Shenk T. Human cytomegalovirus inhibits transcription of the CC chemokine MCP-1 gene. J Virol. 1999; 73:404–10.
Article
18). Murayama T, Mukaida N, Sadanari H, Yamaguchi N, Khabar KS, Tanaka J, et al. The immediate early gene 1 product of human cytomegalovirus is sufficient for upregulation of interleukin-8 gene expression. Biochem Biophys Res Commun. 2000; 279:298–304.
Article
19). Poole E, Atkins E, Nakayama T, Yoshie O, Groves I, Alcami A, et al. NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86. J Virol. 2008; 82:4250–6.
20). Le VT, Trilling M, Hengel H. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb'-encoded modulation of TNF-alpha signaling. J Virol. 2011; 85:13260–70.
21). Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood. 2007; 110:937–45.
22). Taylor RT, Bresnahan WA. Human cytomegalovirus IE86 attenuates virus- and tumor necrosis factor alpha-induced NFkappaB-dependent gene expression. J Virol. 2006; 80:10763–71.
23). Browne EP, Shenk T. Human cytomegalovirus UL83-coded pp65 virion protein inhibits antiviral gene expression in infected cells. Proc Natl Acad Sci U S A. 2003; 100:11439–44.
Article
24). Abate DA, Watanabe S, Mocarski ES. Major human cytomegalovirus structural protein pp65 (ppUL83) prevents interferon response factor 3 activation in the interferon response. J Virol. 2004; 78:10995–1006.
Article
25). Stamminger T, Gstaiger M, Weinzierl K, Lorz K, Winkler M, Schaffner W. Open reading frame UL26 of human cytomegalovirus encodes a novel tegument protein that contains a strong transcriptional activation domain. J Virol. 2002; 76:4836–47.
Article
26). Munger J, Yu D, Shenk T. UL26-deficient human cytomegalovirus produces virions with hypophos-phorylated pp28 tegument protein that is unstable within newly infected cells. J Virol. 2006; 80:3541–8.
Article
27). Mathers C, Schafer X, Martínez-Sobrido L, Munger J. The human cytomegalovirus UL26 protein antagonizes NF-kappaB activation. J Virol. 2014; 88:14289–300.
28). Baillie J, Sahlender DA, Sinclair JH. Human cytomegalovirus infection inhibits tumor necrosis factor alpha (TNF-alpha) signaling by targeting the 55-kilodalton TNF-alpha receptor. J Virol. 2003; 77:7007–16.
29). Jarvis MA, Borton JA, Keech AM, Wong J, Britt WJ, Magun BE, et al. Human cytomegalovirus attenuates interleukin-1beta and tumor necrosis factor alpha pro-inflammatory signaling by inhibition of NF-kappaB activation. J Virol. 2006; 80:5588–98.
30). Montag C, Wagner J, Gruska I, Hagemeier C. Human cytomegalovirus blocks tumor necrosis factor alpha- and interleukin-1beta-mediated NF-kappaB signaling. J Virol. 2006; 80:11686–98.
Full Text Links
  • JBV
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr